# Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.

> **NCT01884675** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Ambrisentan 5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01884675
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884675, "Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01884675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*